Abstract:Background and aims. Osteopontin (OPN) is known to be associated with metastasis in many types of cancers. Since OPN is a highly phosphorylated and glycosylated protein, the modification after transcription is very important to its function. In hepatocellular carcinoma (HCC), the elevated expression of OPN at mRNA levels and its relationship with metastasis and poorer prognosis of-the patients have been reported. However, the prognostic impact of OPN at protein levels on the patients with hepatitis B virus (HBV)-related HCC after hepatectomy is still limited.Patients and methods. The expression of OPN was examined at protein level by using immunohistochemistry in 72 patients who underwent hepatectomy for HBV-related HCC, and its prognostic significance in disease-free and overall survival of the patients was also analyzed by log-rank test and multivariate Cox regression analyses.Results. Thirty-nine of 72 (54.17%) HBV-related HCC specimens were positive for OPN with cytoplasmic staining. OPN was highly expressed in the specimens with capsular infiltration compared to those without (P < 0.05), and also was significantly related with portal vein invasion (P < 0.01) and lymph node invasion (P < 0.01). The mean disease-free survival (DFS) was only 13.55 +/- 114.77 months when the HBV-related HCC specimens highly expressed OPN compared to 36,00 +/- 18.68 months for those with low expression (P < 0.001). The overall survival (OS) of the patients was 18.63 +/- 17.28 months when the HCC over-expressed OPN compared to 42.59 +/- 16.85 months for HCC with the low expressed OPN (P < 0.001). Multivariate analysis showed that OPN over-expression was the strongest independent adverse prognostic factor for both DFS (P = 0.01) and OS (P = 0.014).Conclusions. OPN over-expression was closely related to capsular infiltration, venous invasion, lymph node metastasis, and also with worse prognosis, suggesting that OPN might be deemed as a useful molecular marker for predicting the prognosis of HCC. (c) 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Thrombin is a Therapeutic Target for Metastatic Osteopontin-Positive Hepatocellular Carcinoma.

Abstract A16: Thrombin Promotes Hepatocellular Carcinoma Metastasis Via Mediating Osteopontin-Dependent Tumor Growth and Adhesion Activity

Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma

Thrombin Cleavage of Osteopontin Controls Activation of Hepatic Stellate Cells and is Essential for Liver Fibrogenesis

Osteopontin is A Promoter for Hepatocellular Carcinoma Metastasis: A Summary of 10 Years of Studies

Abstract 2695: Osteopontin Regulated Epithelial-Mesenchymal Transition Via PI3K/AKT Signaling Pathway in Hepatocellular Carcinoma.

Osteopontin Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Through Regulating Vimentin.

Osteopontin Promotes Hepatocellular Carcinoma Invasion by Up-Regulating MMP-2 and Upa Expression.

Prognostic Significance of Osteopontin in Hepatitis B Virus-Related Hepatocellular Carcinoma

Combination of Osteopontin with Peritumoral Infiltrating Macrophages is Associated with Poor Prognosis of Early-Stage Hepatocellular Carcinoma after Curative Resection

Osteopontin Promotes Hepatocellular Carcinoma Progression Via the PI3K/AKT/Twist Signaling Pathway

Down-regulation of Osteopontin Inhibits Metastasis of Hepatocellular Carcinoma Cells Via a Mechanism Involving MMP-2 and Upa.

Osteopontin, a Single Marker for Predicting the Prognosis of Patients with Tumor‐node‐metastasis Stage I Hepatocellular Carcinoma after Surgical Resection

C-C Chemokine Receptor Type 1 Mediates Osteopontin-Promoted Metastasis in Hepatocellular Carcinoma

Overexpression of Osteopontin in Hepatocellular Carcinoma and Its Relationships with Metastasis, Invasion of Tumor Cells

The Prognostic Significance of Preoperative Plasma Levels of Osteopontin in Patients with TNM Stage-I of Hepatocellular Carcinoma.

[Osteopontin Promotes the Malignant Phenotypes of Human Hepatocellular Carcinoma Cell Line SMMC-7721].

Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection

Relative Analysis of OPN and Its Related Signal Molecules in Hepatocellular Carcinoma

Osteopontin Promoter Polymorphisms at Locus -443 Significantly Affect the Metastasis and Prognosis of Human Hepatocellular Carcinoma.

Osteopontin and hepatocellular carcinoma